acutephas
serolog
respons
cohort
patient
revers
transcript
pcr
rtpcr
merscov
diseas
admit
seoul
nation
univers
snu
hospit
seoul
south
korea
snu
borama
medic
center
seoul
snu
bundang
hospit
seongnam
south
korea
previous
report
nine
patient
sever
diseas
defin
requir
supplement
oxygen
mechan
ventil
clinic
viral
load
cytokin
profil
previous
report
follow
patient
sever
diseas
patient
c
f
g
mild
diseas
patient
k
l
n
p
year
serum
sampl
collect
month
month
diseas
onset
use
investig
longterm
kinet
durat
antibodi
respons
form
basi
report
clinic
characterist
earli
immunolog
respons
origin
present
cohort
patient
summar
technic
appendix
tabl
reason
lack
followup
patient
transfer
care
anoth
clinic
unit
patient
refus
followup
patient
j
q
death
patient
b
e
h
patient
b
e
die
acut
phase
ill
patient
h
discharg
receiv
rehabilit
care
given
diagnosi
aspir
pneumonia
die
month
diseas
onset
studi
approv
institut
ethic
review
board
seoul
nation
univers
hospit
approv
human
strain
use
tissu
cultur
infecti
dose
assay
microneutr
assay
plaquereduct
neutral
test
prnt
subset
serum
sampl
also
test
strain
outbreak
south
korea
merscov
heat
inactiv
serum
sampl
min
carri
serolog
test
perform
merscov
prnt
use
plaquereduct
cutoff
microneutr
test
pseudoparticl
neutral
test
ppnt
describ
onlin
technic
appendix
use
merscov
elisa
kit
ei
euroimmun
luebeck
germani
detect
human
igg
merscov
spike
protein
assay
serum
sampl
duplic
perform
assay
accord
manufactur
instruct
assay
includ
calibr
defin
upper
limit
refer
rang
noninfect
human
upper
limit
serv
cutoff
valu
assay
made
semiquantit
calcul
ratio
extinct
patient
sampl
extinct
calibr
ratio
consid
neg
ratio
consid
posit
ratio
consid
borderlin
includ
known
posit
neg
control
serum
sampl
assay
denot
antibodi
titer
reciproc
calcul
peak
viral
load
sputum
ppnt
microneutr
antibodi
titer
mer
elisa
optic
densiti
od
ratio
mer
patient
use
descript
statist
spearman
correl
coeffici
calcul
correl
peak
viral
load
sputum
acut
phase
ill
serolog
respons
antibodi
titer
mer
elisa
od
ratio
differ
time
diseas
onset
also
test
correl
durat
viral
shed
serolog
respons
signific
level
exclud
miss
data
main
analys
sensit
analysi
perform
imput
valu
recent
test
patient
sever
diseas
mild
diseas
p
fisher
exact
test
antibodi
titer
followup
figur
panel
antibodi
titer
patient
c
f
acutephas
antibodi
titer
declin
year
later
patient
g
k
n
acut
phase
peak
antibodi
titer
rang
declin
titer
patient
c
f
g
k
n
patient
sever
diseas
mild
diseas
antibodi
titer
acutephas
serum
sampl
collect
day
diseas
onset
continu
detect
antibodi
titer
ppnt
titer
microneutr
assay
titer
elisa
ratio
year
ill
onset
tabl
figur
panel
b
mer
antibodi
titer
wane
first
month
diseas
onset
especi
patient
high
antibodi
titer
wane
antibodi
titer
month
year
diseas
onset
less
steep
year
infect
patient
mild
diseas
requir
supplement
oxygen
mechan
ventil
neg
result
microneutr
assay
elisa
posit
ppnt
titer
titer
tabl
although
design
mild
diseas
patient
except
patient
p
chest
infiltr
xray
indic
lung
parenchym
patholog
kinet
antibodi
product
seen
ppnt
microneutr
test
elisa
compar
tabl
suggest
test
could
use
detect
merscov
antibodi
patient
past
infect
one
year
infect
patient
antibodi
titer
also
antibodi
detect
ppnt
microneutr
assay
elisa
one
patient
l
margin
titer
posit
ppnt
microneutr
assay
elisa
year
infect
correl
coeffici
ppnt
titer
microneutr
assay
titer
elisa
titer
viru
use
serolog
test
prototyp
merscov
emc
clade
viru
viru
patient
expos
caus
outbreak
south
korea
clade
b
viru
confirm
neutral
antibodi
titer
clade
b
virus
significantli
differ
test
pair
serum
sampl
merscov
patient
variou
level
microneutr
antibodi
respons
emc
microneutr
assay
use
clade
viru
clade
b
viru
outbreak
south
korea
titer
similar
within
dilut
confirm
neutral
epitop
merscov
antigen
conserv
technic
appendix
tabl
peak
viral
load
sputum
correl
antibodi
titer
elisa
od
ratio
acut
phase
ill
month
ill
month
ill
technic
appendix
tabl
howev
found
strong
posit
correl
durat
viru
detect
antibodi
titer
measur
elisa
time
point
technic
appendix
tabl
defin
durat
viru
detect
day
symptom
onset
neg
pcr
convers
median
durat
viru
shed
day
interquartil
rang
day
patient
f
receiv
corticosteroid
therapi
robust
antibodi
respons
tabl
howev
small
number
patient
given
treatment
evalu
qualiti
statist
analysi
possibl
cohort
patient
previous
report
sever
ill
associ
higher
neutral
antibodi
respons
elisa
od
acut
phase
ill
analysi
antibodi
titer
year
ill
show
higher
antibodi
titer
continu
persist
least
year
patient
highest
peak
antibodi
titer
antibodi
titer
wane
first
month
infect
stabil
next
month
pattern
antibodi
product
contrast
pattern
report
patient
microneutr
titer
whose
titer
declin
undetect
level
within
month
microneutr
test
immunofluoresc
antibodi
ifa
assay
elisa
patient
k
l
n
p
design
nonsever
diseas
given
supplement
oxygen
therapi
even
though
except
patient
p
evid
lung
parenchym
diseas
patient
k
n
manifest
robust
antibodi
respons
acut
phase
ill
earli
convalesc
titer
still
present
year
later
patient
robust
serolog
antibodi
titer
develop
acut
phase
ill
patient
remain
seroneg
margin
antibodi
titer
year
infect
poor
antibodi
respons
result
symptomat
diseas
person
asymptomat
mild
infect
without
sever
lung
parenchym
diseas
expect
develop
detect
merscov
antibodi
conclus
implic
seroepidemiolog
studi
three
studi
investig
kinet
longterm
antibodi
persist
patient
merscov
ill
survivor
merscov
outbreak
jordan
april
follow
serolog
test
month
month
infect
patient
merscov
infect
consid
probabl
merscov
infect
posit
serolog
result
togeth
epidemiolog
link
confirm
mer
patient
seven
patient
symptomat
acut
upper
respiratori
diseas
outbreak
radiolog
evid
lower
lung
patholog
chest
radiolog
examin
data
patient
detect
antibodi
elisa
ifa
assay
detect
antibodi
microneutr
test
month
month
infect
titer
rang
howev
patient
robust
serolog
respons
includ
studi
select
bia
without
exclud
definit
studi
saudi
arabia
patient
merscov
infect
follow
month
month
month
patient
infect
test
merscov
elisa
ifa
assay
patient
sever
pneumonia
nonsever
pneumonia
upper
respiratori
symptom
asymptomat
infect
identifi
contact
trace
patient
pneumonia
antibodi
posit
elisa
ifa
assay
month
infect
posit
elisa
month
infect
posit
ifa
assay
month
infect
contrast
patient
mild
upper
respiratori
tract
infect
asymptomat
infect
posit
elisa
ifa
assay
month
infect
data
compar
suggest
milder
infect
less
like
elicit
serolog
respons
howev
studi
provid
data
viru
neutral
antibodi
second
studi
saudi
arabia
report
healthcar
worker
realtim
merscov
infect
detect
elisa
antibodi
titer
year
infect
healthcar
worker
detect
microneutr
antibodi
titer
high
antibodi
titer
wane
antibodi
titer
also
demonstr
patient
sever
acut
respiratori
infect
antibodi
titer
peak
month
diseas
onset
declin
undetect
level
serum
sampl
igg
test
microneutr
test
respect
month
infect
geometr
mean
microneutr
antibodi
titer
drop
month
month
infect
remain
level
month
volunt
experiment
infect
human
cov
neutral
antibodi
titer
peak
week
infect
fell
consider
week
infect
declin
close
baselin
level
year
howev
human
cov
infect
mainli
upper
respiratori
tract
unlik
pathogen
sever
acut
respiratori
syndrom
mer
invas
lung
parenchyma
often
dissemin
system
convalescentphas
plasma
therapi
propos
treatment
option
acut
respiratori
diseas
like
mer
specif
antimicrobi
treatment
avail
data
indic
plasma
high
merscov
antibodi
titer
like
avail
patient
recov
sever
mer
diseas
titer
substanti
wane
within
first
month
ill
although
lower
level
merscov
antibodi
maintain
longer
period
use
convalescentphas
patient
plasma
treatment
necessari
assess
antibodi
titer
potenti
donor
collect
ensur
good
antibodi
titer
neutral
test
like
optim
assay
assess
plasma
use
therapi
data
indic
elisa
correl
well
neutral
titer
elisa
might
suitabl
screen
test
select
person
plasma
donat
one
limit
work
viru
use
neutral
test
clade
viru
merscov
emc
use
assay
viru
patient
infect
caus
outbreak
south
korea
clade
b
viru
domin
viru
clade
current
circul
arabian
peninsula
shown
clade
b
virus
differ
antigen
neutral
epitop
although
genet
distinct
use
subset
serum
sampl
studi
confirm
neutral
antibodi
titer
obtain
clade
emc
viru
similar
obtain
clade
b
viru
strain
outbreak
south
korea
conclus
find
support
extend
research
other
suggest
serolog
test
merscov
antibodi
identifi
patient
merscov
infect
serolog
respons
viru
variabl
robust
often
undetect
diseas
mild
thu
merscov
seroepidemiolog
studi
detect
fraction
infect
occur
popul
probabl
markedli
underestim
extent
mild
infect
take
place
find
also
show
mer
elisa
good
neutral
test
detect
antibodi
year
infect
posit
elisa
result
requir
confirm
neutral
test
fals
posit
avoid
seroepidemiolog
assay
peiri
unpub
data
convalescentphas
plasma
harvest
mani
month
year
diseas
patient
surviv
merscov
infect
plasma
high
antibodi
titer
like
obtain
first
month
convalesc
person
sever
diseas
patient
time
frame
like
frail
approach
challeng
